At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 26 enrolled
Drug / intervention
Ixazomib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia
In Brief
A Phase 2 clinical trial evaluating Ixazomib, Dexamethasone, and 1 other intervention for Waldenstrom's Macroglobulinemia. Completed, enrolled 26 participants across 1 site.
Detailed Summary
This research study is evaluating a drug called ixazomib (also known as MLN9708) in combination with dexamethasone and rituximab (the regimen is called IDR) as a possible treatment for Waldenstrom's Macroglobulinemia (WM).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsWaldenstrom's Macroglobulinemia
CountriesUnited States
CollaboratorsMillennium Pharmaceuticals, Inc.
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 2015
Enrollment StartApr 2015
Primary CompletionNov 2019
TodayJul 2026
First PostedMar 27, 2015
Enrollment StartApr 1, 2015
Primary CompletionNov 1, 2019
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 11.3 years ago
Interventions
Ixazomibdrug
Doses given on Days 1, 8, and 15 in induction and maintenance cycles.
Dexamethasonedrug
Doses given on Days 1, 8, and 15 in induction and maintenance cycles.
Rituximabdrug
Doses given on Day 1 of induction and maintenance cycles.